GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
GeneDx faces short-term downward pressure due to concerns over proposed Medicare reimbursement rate cuts, despite strong recent growth and operational milestones.
Investors are reacting to a proposed 2027 Medicare lab rate update that could reduce reimbursement by up to 15% for several key tests. This potential regulatory change threatens future revenue and margins, contributing to recent stock price volatility and downward pressure.
TipRanks